Cavhanza Tablet, Orally Disintegrating
NDC 70709-191
Product Information
Cavhanza (nilotinib) is a NDA-approved product labeled by Cycle Pharmaceuticals Ltd. This medication is typically used as a bcr-abl tyrosine kinase inhibitors [moa]. It is supplied as a white tablet, orally disintegrating for oral administration. This product entry covers the primary NDC 70709-191 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
15;5
Code Structure Chart
Product Details
What is NDC 70709-191?
What are the uses of this product?
What are Active Ingredients of this product?
- NILOTINIB 60 mg/1 - antineoplastic agent
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- NILOTINIB (UNII: F41401512X)
- NILOTINIB (UNII: F41401512X) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- HYPROMELLOSE ACETATE SUCCINATE, UNSPECIFIED (UNII: A7ZHS2RJ34)
- BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- MANNITOL 1-ACETATE (UNII: 0D957QQ54N)
- CROSPOVIDONE (UNII: 2S7830E561)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- STARCH, CORN (UNII: O8232NY3SJ)
Which are the Pharmacologic Classes of this product?
- Bcr-Abl Tyrosine Kinase Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 2B6 Inducers - [MoA] (Mechanism of Action)
- Cytochrome P450 2C8 Inducers - [MoA] (Mechanism of Action)
- Cytochrome P450 2C8 Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 2D6 Inhibitors - [MoA] (Mechanism of Action)
- Kinase Inhibitor - [EPC] (Established Pharmacologic Class)
- P-Glycoprotein Inhibitors - [MoA] (Mechanism of Action)
- UGT1A1 Inhibitors - [MoA] (Mechanism of Action)
* Please review the full disclaimer at the bottom of this page.